Beta Bionics Faces Securities Probe Over Patient Growth Metrics

A sharp deceleration in new patient acquisitions has triggered a formal investigation into Beta Bionics, as law firm Johnson Fistel examines whether the company misled shareholders regarding its 2025 financial trajectory. The inquiry centers on whether executives failed to disclose material risks behind the sudden decline in growth momentum.

The investigation follows a January 8, 2026, disclosure where Beta Bionics reported that new patient starts for the fourth quarter reached at least 5,581. While this figure represented a 36% year-over-year increase, it fell significantly short of market expectations. The data signaled a major cooling period for the firm, which had posted a 68% growth rate in the previous quarter.

Investors who incurred losses following these disclosures are now being evaluated for potential class action claims. Johnson Fistel is probing whether the company’s public statements and growth forecasts provided an accurate picture of its business outlook. Those impacted by the stock's performance are encouraged to contact attorney James Baker to review their legal standing, with no upfront cost or obligation for those participating in the firm’s review.